IPHA Stock Risk & Deep Value Analysis

Innate Pharma S.A.

Healthcare • Biotechnology

DVR Score

7.5

out of 10

Solid Pick

The Bottom Line on IPHA

We analyzed Innate Pharma S.A. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran IPHA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Oct 9, 2025•Run Fresh Analysis →

About Innate Pharma S.A. (IPHA)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

small

Market Cap

$193.81M

IPHA Deep Value Analysis

Innate Pharma presents 10x potential due to its differentiated NK cell-targeting approach and a critical Phase 3 asset, monalizumab, partnered with AstraZeneca. This partnership significantly de-risks financing and validates their vision for a vast oncology market. Upcoming Phase 3 results are a major binary catalyst. While financial health is reliant on milestones and future royalties, and the risk of clinical failure is high, the company possesses strong competitive advantages and experienced leadership, preventing it from being a 'dud' despite the inherent volatility and potential for total loss.

IPHA Financial Health Metrics

Market Cap

$193.81M

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.

More Resources to Boost Your Portfolio

Explore our other guides and tools to maximize your investment returns